CellSourceCellSource Co.,Ltd.4880東証プライムサービス業FY ending Oct 2025, consolidated, J-GAAP
About 74% of CellSource's sales come from Regenerative medicine related business, with Consumer business making up much of the rest.
Out of every ¥100 of sales, about ¥20 is left as operating profit.
For every ¥100 CellSource sells, how much goes where, and how much is kept.
Margin funnel (derived from reported values)Gross margin 71.6% → Operating margin 20.3% → Net margin 12.4%
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.